Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Golling, M; Becker, T; Broelsch, C; Candinas, D; Faust, D; Fischer, L; Geissler, E; Graeb, C; Iberer, F; Klupp, J; Kraus, T; Müller, AR; Neuhaus, P; Strassburg, CP; Wolff, M; Zülke, C; Bechstein, WO.
Consensus-recommendations for sirolimus in liver transplantation.
Z Gastroenterol. 2004; 42(11):1333-1340
Doi: 10.1055/s-2004-813703
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Iberer Florian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Sirolimus is an m-TOR inhibitor without renal side effects and potentially protects against the development of malignancy. Due to a higher incidence of complications in two trials and an official warning in the drug information, the use of Sirolimus in liver transplantation is limited. The participants of this consensus meeting had to analyse and evaluate the literature with respect to the potential role of Sirolimus in liver transplantation. This consensus statement follows the scheme normally employed for the presentation of guidelines including the grading of evidence (1a-5) and the extent of recommendation (A-C). Moreover, the consensus included the experience of the authors with respect to the handling of Sirolimus after liver transplantation.
- Find related publications in this database (using NLM MeSH Indexing)
- Drug Therapy, Combination -
- Evidence-Based Medicine -
- Graft Rejection - drug therapy
- Humans -
- Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use
- Liver Transplantation - immunology
- Practice Guidelines as Topic -
- Sirolimus - adverse effects Sirolimus - therapeutic use
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Sirolimus
- liver transplantation
- consensus conference